WaveMan
WaveMan · Company
AVR · Anteris Technologies Global Corp.
> Search tickers & screens ⌘K
LIVE
← All companies

AVR Anteris Technologies Global (AVR) Insider Trading, Ownership & Congress Trades

Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0002011514
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
83
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $727.9K priced

What the filings say about AVR

Insiders, 180 days
-$13.4M net sold
2 buyers · 1 seller · 0% of sales under a 10b5-1 plan

Anteris Technologies Global insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Anteris Technologies Global Corp. insiders sold a net $13.4M of stock across 20 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
L1 Capital Pty Ltd
BUY
2026-10-08 SECtraded 2026-10-06
272,695
$2.0M
-11.4%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (5 buys, 13 sales), the last on Oct 5, 2026.
  • The trade is 4.3% of the 6,358,271 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider L1 Capital Pty Ltd bought about $2.0M of AVR on Oct 6, 2026; 83 funds added in the latest 13F quarter.
L1 Capital Pty Ltd
BUY
2026-10-06 SECtraded 2026-10-05
648,455
$4.9M
-12.0%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (4 buys, 13 sales), the last on Oct 2, 2026.
  • The trade is 5.1% of the 12,778,380 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider L1 Capital Pty Ltd bought about $4.9M of AVR on Oct 5, 2026; 83 funds added in the latest 13F quarter.
L1 Capital Pty Ltd
BUY
2026-10-06 SECtraded 2026-10-02
236,354
$1.8M
-12.0%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (3 buys, 13 sales), the last on Oct 1, 2026.
  • The trade is 1.9% of the 12,129,925 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider L1 Capital Pty Ltd bought about $1.8M of AVR on Oct 2, 2026; 83 funds added in the latest 13F quarter.
L1 Capital Pty Ltd
BUY
2026-10-01 SEC
322,940
$2.5M
-22.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (2 buys, 13 sales), the last on Sep 30, 2026.
  • The trade is 6.2% of the 5,200,767 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider L1 Capital Pty Ltd bought about $2.5M of AVR on Oct 1, 2026; 83 funds added in the latest 13F quarter.
L1 Capital Pty Ltd
BUY
2026-10-01 SECtraded 2026-09-30
74,286
$573.5K
-22.2%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (1 buy, 13 sales), the last on Aug 28, 2026.
  • The trade is 1.5% of the 4,877,827 shares held after it.
  • No other insider bought within 30 days.
  • 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider L1 Capital Pty Ltd bought about $573.5K of AVR on Sep 30, 2026; 83 funds added in the latest 13F quarter.
20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 15 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$13.4M over 180 days
-$9.8M over 90 days · -$13.5M of it by a 10%+ holder
below 89% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
83 funds bought in last quarter
more than 59% of Medical Devices
Revenue
-29.2% year over year
below 92% of Medical Devices
Margin
-4921.3% net margin
the lowest in Medical Devices
Buybacks
no share repurchases reported
Short interest
10.1% of the float short (float per yahoo 2026-10-26) · 7.7 days to cover · settled 2026-09-30
more than 77% of Medical Devices
What changed in the last 30 days
Oct 8Insider L1 Capital Pty Ltd bought $11.7M (5 trades, Sep 30 to Oct 6)

Watch AVR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+7.3%12M
-40%+3%+46%+89%2025-102025-122026-022026-042026-062026-082026-10 2026-01-22 · L1 Capital Pty Ltd bought $28.8M2026-10-05 · L1 Capital Pty Ltd bought $4.9M2026-07-30 · L1 Capital Pty Ltd sold $4.6M2026-08-04 · L1 Capital Pty Ltd sold $4.0M2026-08-03 · L1 Capital Pty Ltd sold $3.9M2026-08-11 · L1 Capital Pty Ltd sold $3.5M2026-10-01 · L1 Capital Pty Ltd bought $2.5M2026-08-10 · L1 Capital Pty Ltd sold $2.3M2026-10-06 · L1 Capital Pty Ltd bought $2.0M2026-07-27 · L1 Capital Pty Ltd sold $1.9M2026-10-02 · L1 Capital Pty Ltd bought $1.8M2026-07-28 · L1 Capital Pty Ltd sold $1.7M2026-08-06 · L1 Capital Pty Ltd sold $1.4M2026-07-29 · L1 Capital Pty Ltd sold $1.3M2026-09-30 · L1 Capital Pty Ltd bought $573.5K2026-07-31 · L1 Capital Pty Ltd sold $397.0K2026-07-24 · L1 Capital Pty Ltd sold $187.0K2026-08-05 · L1 Capital Pty Ltd sold $120.0K2026-06-02 · Knight Susan Elizabeth bought $102.2K2026-08-28 · L1 Capital Pty Ltd sold $68.9K2026-01-29 · Medtronic plc filed a 5%+ stake (16.2%)2026-01-29 · Covidien Group S.a.r.l. filed a 5%+ stake (16.2%)
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AVR: institutional holders (13F)

13F holdings, latest reported quarter
L1 Capital Pty Ltd
7,789,000 sh
$76.7M
FMR LLC
6,868,086 sh
$67.7M
Nantahala Capital Management, LLC
6,766,670 sh
$66.7M
BlackRock, Inc.
5,771,213 sh
$56.8M
Sio Capital Management, LLC
5,545,984 sh
$54.6M

Congress trades in AVR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Medtronic plc
Activist 13D · 2026-01-29
16.2%
Covidien Group S.a.r.l.
Activist 13D · 2026-01-29
16.2%

AVR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

AVR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Pacific Basin Fund
$14.1M position · as of 2026-07-31
1.2%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$1.1M position · as of 2026-06-30
0.7%
Fidelity International Small Cap Opportunities Fund
$10.7M position · as of 2026-07-31
0.6%
Fidelity Series International Small Cap Fund
$15.6M position · as of 2026-07-31
0.6%
JNL Multi-Manager International Small Cap Fund
$2.5M position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$344.8K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $13.4M sold by insiders over 180 days, 83 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

AVR financials

Revenue growth
-29.2%
XBRL, annual
Net margin
-4921.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-4,619%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$88.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-1,835.23x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-75.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-66.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-75.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$334.9M
market value at close 2026-10-27 on 2026-08-10 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-15.1%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Revenue$1.9M$2.7M
Operating income-$93.9M-$78.4M
Net income-$94.1M-$76.3M
EPS (diluted)-2.55-3.68
Operating cash flow-$77.8M-$61.2M
Cash$6.7M$70.5M
Long-term debt$22.0K$0
SEC XBRL, fiscal years, as known on 2026-10-28

AVR Stock Sonar score 6/7 axes

Find similar shapesCompare

AVR ranks highest on institutional and government (59th percentile) and financial health (47th), and lowest on growth (8th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
27
Inputs
  • Return on equity-75.1% · 31 pct, sector of 183
  • Return on assets-66.3% · 25 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-75.7% · 24 pct, sector of 188
Financial health
47
Inputs
  • Debt to equity0.00x · 93 pct, sector of 159
  • Cash flow to debt-1835.23x · 0 pct, sector of 150
Growth
8
Inputs
  • Revenue growth, YoY-29.2% · 8 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
42
Inputs
  • Net Form 4 buying (codes P and S), 180d-$13.4M · 9 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Institutional and government
59
Inputs
  • Funds adding, latest quarter83 · 59 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+10.1% · 19 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.8% · 60 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AVR filings, in plain words

Are Anteris Technologies Global insiders buying or selling AVR?

In the 180 days to 2026-10-28, Anteris Technologies Global insiders were net sellers, a net $13.4M: $11.8M of purchases and $25.2M of sales reported on Form 4, by 2 buyers and 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Anteris Technologies Global insiders were net sellers of AVR, a net $13.4M across purchases and sales reported on Form 4 by 2 buyers and 1 seller. Most of that figure, $13.5M, came from a holder of 10% or more rather than an officer or director. None of the 13 insider sales was flagged as made under a Rule 10b5-1 plan. The latest 5% ownership filing is a 13D by Medtronic plc, filed 2026-01-29, for 16.2% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies